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Use of fresh-frozen plasma in 2012 at the Fondazione Ca' Granda Hospital 
of Milan: assessment of appropriateness using record linkage techniques 
applied to data routinely recorded in various hospital information systems 
Monica Lanzoni1, Barbara Olivero1, Andrea Artoni1, Maurizio Marconi1, Elisabetta Raspollini1, 
Silvana Castaldi1,2
1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; 2Department of Biomedical Sciences for 
Health, University of Milan, Milan, Italy 
Background. The Quality Unit of a research and teaching hospital in Milan assessed the 
increased clinical use of fresh-frozen plasma in patients treated during 2012 in order to evaluate the 
appropriateness of this use.
Materials and methods. For each patient in the study, a pathology profile was generated by means 
of record linkage techniques involving data collected through different information systems. Patients' 
information was combined using the patient identifier key generating pathology profiles exported 
to an Excel file. The profiles were reviewed by two haematologists who identified 101 potentially 
inappropriate treatments for which the medical records had to be reviewed manually.
Results. In 2012, 490 patients were transfused and for 473 cases the automatic record linkage 
provided a complete profile. The information relating to the remaining patients did not match, 
mainly because the patients underwent outpatient procedures for which clinical information is not 
automatically recorded. In the overall audit only 13 treatments were judged inappropriate. 
Discussion. Our study supports the view that record linkage techniques applied to data routinely 
recorded in different hospital information systems could be potentially extended to support clinical audits, 
enabling the generation of automated patient profiles that can be easily evaluated, relegating manual 
checks on medical records to doubtful cases only. Moreover, the method applied in this study allows the 
analysis of a full set of cases instead of sample surveys, increasing the robustness of the audit results.
Keywords: plasma, clinical governance assessment, health information systems, record linkage, 
pharmacoepidemiology.
Introduction
Plasma is a blood component that can be derived 
from whole blood by separation or plasmapheresis. The 
resulting fresh plasma is frozen within given time limits 
at temperatures that can adequately preserve the activity 
and the quantity of the labile coagulation factors1. 
In Italy, the Blood System is run under a public 
governance scheme2. The Italian National Blood Centre 
is the competent authority that coordinates and supervises 
the 21 Regional Blood Transfusion Centres with the aim 
of guaranteeing homogeneous standards of quality and 
safety across the 310 exclusively public and hospital-
based blood establishments. Blood is collected only 
from voluntary and non-remunerated donors. One of 
the goals of the Blood System is to reach national self-
sufficiency for blood, blood components and plasma-
derived medicines (i.e., albumin, coagulation factors and 
immunoglobulins). Regions send the plasma collected 
by blood establishments, and not used for transfusion 
purposes, to authorised manufacturers that produce 
plasma-derived medicines under a toll fractionation 
agreement. Regions retain ownership/property of the raw 
materials and the equivalent derived products throughout 
the whole process. Both the management and control of 
the production process and the distribution of plasma 
for third-party processing are carried out by Regional 
Blood Transfusion Centres. If the amount of plasma 
collected remains constant but the plasma needs for 
clinical use increase, the quantity of plasma available 
for toll fractionation and production of plasma-derived 
medicines decreases and hospitals are therefore compelled 
to increase their intake of plasma-derived medicines 
bought on the free market, normally at greater cost3-5.
Fresh-frozen plasma (FFP) is the most misused 
blood component in the clinical setting6-9. Until the 
1990s this led to an unjustified exposure of patients to 
the risk of contracting viral infections3-6. However, the 
introduction of new screening tests including nucleic acid 
amplification tests, has significantly mitigated this risk. 
Currently, therefore, the major clinical risks of plasma use 
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are severe transfusion reactions such as allergic reactions, 
transfusion-related acute lung injury and transfusion-
associated circulatory overload and excessive use of 
plasma would mainly translate into economic damage. 
The Fondazione Istituto di Ricovero e Cura a 
Carattere Scientifico Ca' Granda Ospedale Maggiore 
Policlinico (Fondazione hereafter) is a research and 
teaching hospital in Milan. It has three emergency units 
(adult, paediatric and obstetric), kidney, liver, lung, 
cornea and bone marrow transplant centres, a Medical 
School, several post-graduate schools and some three-
year courses for healthcare providers of the Faculty of 
Medicine and Surgery of the University of Milan. It also 
hosts a training centre for postgraduate courses and first 
and second level Master's Degrees.
During 2012, the Fondazione was obliged to 
purchase immunoglobulins on the market because the 
hospital Transfusion Centre had been unable to send a 
quantity of plasma for fractionation sufficient to meet 
the needs for the finished product. 
Therefore, during 2013, the strategic management 
leadership of the Fondazione carried out an assessment 
of FFP use and its effect on drug costs. The scope of this 
exercise was two-fold: to obtain sufficient information 
to enable clinical governance measures to be taken if 
inappropriate use was discovered or, if FFP uses proved 
to be justified, to revise the blood donor programmes.
Italian and foreign guidelines on the appropriate use of 
plasma identify correct/incorrect usage areas as shown in 
Table I1-6,10-20. Nevertheless, composition and properties of 
plasma make its inappropriate use quite likely, especially 
when treating the clinical conditions shown in the second 
part of Table I. Such an inappropriate use does not 
necessarily compromise the effectiveness of the treatment 
provided, but it may negatively affect the efficient use of 
resources within the healthcare system. In fact, whenever 
plasma use has been identified as inappropriate, there 
is an equally effective therapeutic treatment at a lower 
cost: for instance, the use of pharmaceutical products 
containing the single coagulation factors the patient needs, 
prothrombin complex concentrates or vitamin K, rather 
than plasma expanders21,22. 
During the 1990s the Transfusion Centre of the 
Fondazione set up a process of computer-aided 
auditing7,8, but this activity had to be discontinued 
following the introduction of regional software which 
did not envisage it.
In order to review plasma uses, it would have been 
quite impractical to conduct a systematic review by 
evaluating manually every medical record of every patient 
who had received a FFP transfusion. For this reason, it 
was decided to set up a record linkage23,24 strategy aimed 
at automatically defining a "pathology profile" of the 
patients treated. Then, appropriateness of FFP use was 
first assessed through the examination of these profiles, 
with integration from medical records if needed, by two 
haematologists assigned to the Transfusion Centre. 
Generally speaking, record linkage techniques allow 
data integration, identifying and matching individual 
records that refer to the same entities from disparate 
databases. This paper focuses on the analytical methods 
adopted and the results obtained through the record 
linkage of information routinely recorded on different 
information systems in the Fondazione concerning 
the same patient and shows the potentialities of record 
linkage for clinical governance programmes.
No ethical approval was needed for the study 
according to regional law 24/12/2012 n. 3, which allows 
the data analysis of hospital medical records for quality 
and appropriateness evaluation programmes.
Materials and methods
Guidelines and evidence published in the literature
The Italian Transfusion System already provides 
several guidelines on FFP use drawn up by Italian, 
European1-6,10-16,20 and international17-19 societies. 
Moreover, in many Italian hospitals the committees 
for the proper use of blood have defined internal 
protocols25-28. All guidelines agree in describing 
as appropriate the FFP use under the pathological 
conditions shown in the upper section of Table I, while 
its use in the clinical conditions shown in the lower 
section is deemed inappropriate since other valid 
therapeutic options exist for such cases29-34.
Data entry and hospital information systems 
Information considered necessary for the assessment 
included: (i) patients' characteristics; (ii) period of 
hospitalisation and of provision of FFP transfusion 
including the number of units transfused; (iii) primary 
and secondary diagnoses at the moment of discharge, 
with indication of all invasive medical and surgical 
procedures performed during the period considered; 
and (iv) blood tests performed throughout the period 
spent in hospital. The laboratory tests assessed in order 
to define the appropriateness or inappropriateness of 
FFP transfusion were, in particular, those concerning the 
patient's coagulation status, such as prothrombin time 
(PT) and its Normalised Ratio, activated thromboplastin 
time (APTT) and its Normalised Ratio, and the levels 
of fibrinogen, fibrinogen degradation products/D-dimer, 
protein S, protein C and antithrombin III.
In order to define a patient's pathology profile (PPP), 
information had to be retrieved from various hospital 
information systems (Table II):
- EMONET (Insiel Mercato SpA, Trieste, Italy): 
an information system of the Transfusion Centre 
which manages the whole workflow of a single 
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FFP utilisation assessment using record linkage techniques
blood component unit from the blood collection 
of the donor to the transfusion to the patient. This 
information system is widely used in Italy and is the 
reference system for the Regional Health Authority.
- ACCENET (Hi.Tech Software Engineering SpA, 
Bagno a Ripoli, Italy): an information system 
in which all the characteristics of every hospital 
admission are registered collecting variables from 
the Hospital Discharge Module (SDO in Italian), 
the summary of every hospital medical record. 
The variables collected are defined by the Ministry 
of Health and the Regional Health Authority for 
systematic data collection for epidemiological and 
economic (hospital payment) purposes. 
- CUPNET (Hi.Tech Software Engineering SpA): 
an information system in which all the services in 
the outpatient setting are registered. The variables 
collected are defined by the Ministry of Health and 
the Regional Health Authority for systematic data 
collection mainly for economic purposes (hospital 
payment) and contain only generic descriptions of 
the activities performed, without reporting patients' 
conditions. 
- CONCERTO (Dedalus Healtcare Systems Group 
SpA, Firenze, Italy): the information system of the 
Laboratory Department which manages the whole 
workflow of a single laboratory test from the medical 
request (internal or external to the hospital) to the 
laboratory report. Some of the variables collected are 
defined by the Ministry of Health and the Regional 
Health Authority for systematic data collection for 
economic purposes (hospital payment).
Table I - Use of FFP deemed appropriate/inappropriate and criteria for assessment.
Appropriate use of FFP
Disease Selection criteria
Congenital or acquired deficiencies of single coagulation factors - If the specific concentrate is NOT available (e.g. factors V and XI).
- If bleeding is ongoing or for bleeding prevention in case of surgery or invasive 
procedures. 
Acquired deficiency of multiple coagulation factors - If PT or APPT ratios >1.5.
- If bleeding is ongoing or in case of significant bleeding risk associated with surgery 
or invasive procedures. 
Severe liver disease - If bleeding is ongoing.
- For bleeding prevention in case of surgery or invasive procedures.
Vitamin K deficiency or on vitamin K antagonist therapy - If prothrombin complex concentrate is not readily available (first-choice treatment).
- In case of intracranial or severe bleeding. 
- In preparation for not deferrable surgery. 
Acute disseminated intravascular coagulation - If bleeding is ongoing or in association with correction of the underlying cause. 
Microvascular bleeding - In case of massive transfusion after trauma or surgical manoeuvre.
Thrombotic microangiopathy (thrombotic thrombocytopenic 
purpura, haemolytic uraemic syndrome, haemolysis, elevated 
liver enzymes and low platelet count - HELLP)
- As substitution fluid.
Hereditary angioedema due to C1-esterase inhibitor deficiency - If the specific C1-inhibitor plasma derivative is not available. 
Whole blood reconstitution for exchange transfusion
Neonates with congenital deficiencies of single coagulation factors - If the specific concentrate is NOT available.
Neonates with deficiency of vitamin K-dependent coagulation 
factors
- If bleeding is ongoing and/or in case of invasive procedure if the specific concentrate 
is NOT available. 
Neonates with disseminated intravascular coagulation - If bleeding in ongoing or in association with correction of the underlying cause. 
Neonates with severe coagulopathy -	 In	case	of	bleeding	risk	(pre-term	infants	at	gestational	age	≤28	weeks	and/or	intubated	
with previous intraventricular haemorrhage for 48/72 hours).
- In case of invasive procedure. 
Contraindications
Congenital IgA deficiency with anti-IgA antibodies in adults 
Inappropriate aims of treatment
Use as plasma expander
Treatment of hypoproteinaemia 
Treatment of immunosuppression
Nutritional purposes
Treatment of haemostasis disorders in chronic liver disease not complicated by haemorrhage 
PT: prothrombin time; APTT: activated partial thromboplastin time; Ig: immunoglobulin.
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Record linkage and construction of patients' 
pathology profiles
The linkage of the variables collected in the different 
information systems on the same patient was achieved 
through the patient's tax code which is the unique 
patient identifier used in the National Health System 
in Italy. It consists of 16 characters (both digits and 
letters) and is assigned to everyone born in Italy and 
to every immigrant by the Inland Revenue Agency. 
It is formulated by means of an algorithm35 that takes 
into account the individual's name, surname and date 
and place of birth. The tax code was not present in one 
of the information systems, EMONET, but, given the 
availability of some of the required information it was 
possible to apply the algorithm used for its calculation 
and thereby automatically generate the first 11 characters 
of the tax code. The link between the variables recorded 
in the transfusion system and the remaining systems 
was therefore made using just the first 11 digits of the 
tax code (ID). After verification that truncation never 
produced coincident 11-character truncations of different 
patients' 16-character tax codes, no ambiguity in the 
assignment of the data selected for each PPP was found, 
and record linkage resulted fully deterministic.
Since the first selection of the records in the different 
information systems was made using only the patient's 
ID, the records retrieved did not necessarily all refer 
to the same hospital admission. In order to obtain a 
profile of the patient on the basis of each individual 
hospital treatment, time consistency was checked as 
Table II - Information needed to generate a patient's pathology profile (PPP) from the hospital information systems and 
selected variables.
Type of variables needed in PPP Name of information system Selected variables
Selection of blood component EMONET Surname, name, gender, date of birth (IDpat.), date of request, request form ID, 
applicant ward, type of request, blood component ID, delivery date, delivery ward, 
single ID code of the blood component unit.
Variable that defines the first subset of data; blood component ID=FFP
Pathological conditions of the 
patient and procedures performed 
during hospitalisation
ACCENET Admission ID, type of activity (standard/day hospital), patient ID, date of admission, 
date of discharge 
Diagnosis IDs (max 6 diagnoses ICD9-CM), date and surgery/procedure ID (max 
6 procedures ICD9-CM), type of discharge, ID of units in which the patient was 
admitted during the hospitalisation.
Variable that defines the first subset of data; patient ID = IDpat identified in 
EMONET selection 
Type of treatment given to the 
patient in an outpatient setting
CUPNET Patient ID, outpatient treatment, date of outpatient treatment.
Variable that defines the first subset of data; patient ID = IDpat identified in 
EMONET selection 
Results from coagulation-related 
blood tests 
CONCERTO Patient ID, date of request, request ID, applicant ward, request test ID, test result 
ID, result value.
Variable that defines the first subset of data; patient ID = IDpat identified in 
EMONET selection
The variables used for record linkage are shown in bold type. 
FFP: fresh-frozen plasma.
shown in Figure 1. Record linkage was then performed 
by subsequent iterations: (i) all FFP units assigned 
(EMONET) during each hospital stay were identified 
by retrieving recipient patients from 2012 and 2013 
hospitalisation databases (ACCENET) in order to 
identify any FFP unit assigned in 2012 during hospital 
stays begun in 2012 and ended in 2012 or 2013; (ii) 
recipient patients were sought among outpatients' ward 
records (CUPNET) for all FFP units not assigned during 
hospital stays. In a second phase, coagulation tests were 
selected in CONCERTO by linking the patient's ID 
with consistent dates of laboratory tests, admission and 
assignment of FFP units. At the end of the record linkage 
procedure, each FFP unit assigned during 2012 was 
identified and linked to a treatment provided to a patient. 
The information selected from each information 
system was then converted into text file format and 
loaded into an ACCESS 2007 format database. Using 
ACCESS the data were processed and the PPP generated 
were exported into Excel format and anonymously 
provided to the clinicians.
Finally, a PPP was generated for all patients for 
whom hospital treatment and/or blood test parameters 
had been identified. An example of a PPP is shown in 
Figure 2.
Assessment of the appropriateness of use of fresh-
frozen plasma 
Two haematologists reviewed the PPP, identifying 
potentially inappropriate treatments. If the two reviewers 
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Figure 1 - Record linkage algorithm for the generation of patients' pathology profiles (PPP).
 FFP: fresh-frozen plasma; ID PAT: patient identification code; PATs: patients; UNIT: unit of fresh-frozen plasma; 
Data ADM: data of hospital admission; Data UNIT: data of transfusion of the fresh-frozen plasma unit; Data 
LAB: data of laboratory test request; Data DISCHARGE: data of discharge; Data Outpatient ID: data of 
outpatient treatments; H ADM: hospital admission.
did not agree, the evaluation of a third senior medical 
doctor of the Transfusion Centre was required. The 
patients' medical records were manually read only in 
cases in which: (i) assessment of a PPP did not enable an 
opinion on the appropriate use of FFP; (ii) information 
on the patient's coagulation status was lacking; (iii) an 
Figure 2 - Example of a patient's pathology profile (PPP). 
 ID PAZ: identification code of the patient in the study; DT LAB: date of laboratory request; ID RIC LAB: 
identification code of laboratory request; PT SEC: prothrombine time; PT RATIO: prothrombine time 
standardised ratio; APTT SEC: activated partial thromboplastin time; APTT RATIO: partial tromboplastin 
time standardised ratio; ID_HOSP: identification code of the hospitalisation; ADM DT: date of admission for 
hospitalisation; TYPE HOSP: type of hospitalisation; N BAGS: number of units transfused; DISC DT: date of 
discharge; DIAGN 1-6: ICD9-CM codes of diagnoses 1 to 6; DT INT1-6: dates of interventions from 1 to 6; 
INT 1-6: ICD9-CM codes of interventions from 1 to 6.
unusual pathology was encountered; or (iv) the doses 
of FFP transfused appeared insufficient.
It was decided not to proceed with the record linkage 
method to assess the appropriateness of transfusions 
in neonatal cases for various reasons. In particular, 
coagulation times in neonates are longer on average 
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than those of adults and not necessary linked to bleeding 
risk. This is even more true in case of preterm infants 
in whom abnormalities in the coagulation tests, unless 
they are particularly significant, and in the absence 
of symptoms or bleeding risk, do not represent an 
indication for an FFP transfusion. With premature 
babies, the complex clinical picture and the impossibility 
of performing daily blood tests leads the record linkage 
method to lack information indispensable to define the 
appropriateness of the FFP transfusion. In these cases, 
the appropriateness of the FFP transfusion could only 
be assessed by a conventional review of the medical 
records. For this reason the description of neonatal cases 
in Table III and the first section of the Table SI reported 
in the online supplementary content, which summarises 
the distribution of Diagnosis-Related Groups and the 
main diagnoses relating to the 78 neonatal cases, is 
shown only as an illustration of the cases dealt with in 
our Transfusion Centre. These cases were not included 
in the final assessment.
Results
During 2012 the Transfusion Centre of Fondazione 
assigned 5,413 units of plasma, of which 5,382 to 
non-anonymous recipients. Recipients are defined 
as anonymous in the rare cases they are admitted to 
the emergency unit without ID documents or when it 
was necessary to give the transfusion before they had 
been identified. The 5,382 units transfused to correctly 
identified subjects corresponded to 1,167 requests for 
a total of 490 patients in 521 hospital admissions or 
outpatient treatments (some patients received more than 
one treatment during the year analysed). 
Using the analytical method proposed it was possible 
to extrapolate, rapidly, plenty of information concerning 
the patients and their clinical workflow from the various 
information systems. First of all it was possible to 
collect statistical data on patients' population (gender, 
age), the number of requests for FFP, the number of 
units transfused, the level of care (hospitalisation or 
emergency unit). This provided a synthetic description 
of the characteristics of the patients analysed (adults/
children) and the settings in which the FFP units had been 
used (medical/surgical or emergency unit) (Table III).
Moreover, it was possible to extrapolate the clinical 
characteristics of the patients analysed. The table 
reported in the online supplementary material shows 
the distributions of the Diagnosis-Related Groups and 
the main diagnoses relating to the hospital treatments 
for 78 neonatal patients, 14 patients aged under 14 and 
403 adult patients who could be assessed on the basis 
of their hospital information. Patients aged under 14 are 
conventionally classified as paediatric and are treated 
in paediatric wards, which is the reason why they are 
assessed separately from the adult cases; the criteria for 
judging plasma transfusion are nevertheless the same as 
those applied to adult patients.
Lastly, it was possible to assess the workload 
distribution between the various operative units showing 
that the departments mainly requesting and transfusing 
FFP are the liver transplant centres, and the surgical, 
intensive care and resuscitation units. This is confirmed 
by the data analysed for appropriateness.
Analysis of the information collected enabled a 
judgment on appropriateness of FFP. The subjects 
assessed, on the basis of the pathological conditions 
deemed suitable for FFP transfusion (Table I), are 
summarised in Table IV. 
Following the analysis of treatment given to 
adult patients, FFP use appeared appropriate in 302 
cases simply on the basis of the consistency of the 
information shown in the PPP. A manual review 
of the paper medical records was necessary in the 
remaining 101 cases, either because the information 
in the PPP was not considered sufficient to express a 
judgment on appropriateness (n=86), or because the 
profile indicated an inappropriate use that nevertheless 
required confirmation (n=15). 
Table III - Characteristics of the patients and the setting of FFP requests identified through record 
linkage.
Type of patient Setting N. of 
treatments Gender
Average age 
(SD)
N. of FFP 
requests 
N. of 
units 
Children
	(≤age	14)
Hospitalisation 92 M=54, F=38 Neonates 78 (0; 0)
14 others (7.9; 4) 206 256
Outpatient unit 4 M=4 6.5; 5.2 23 58
Unknown 3 M=1, F=2 2 age=0; 1 age=13 4 4
Adult 
(>age 14)
Hospitalisation 407* M=211, F=196 57.6; 17.3 901 4,913
Outpatient unit 14 M=10, F=4 49.6; 23.5 32 148
Unknown 1 M=1 49 1 3
Total 521 M=281, F=240 46.7; 27.0 1,167 5,382
* No discharge data are available for four hospitalised subjects. SD: standard deviation; FFP: fresh-frozen plasma.
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At the end of the assessment of the medical records, 
13 patients proved to have received inappropriate 
transfusion of FFP (3.2%). Tests showed that these 
patients' coagulation was within normal limits but 
without haemorrhagic diathesis such as to justify 
transfusion. Moreover, in four cases appropriateness 
criteria were met but the quantity of plasma transfused 
proved insufficient given that a single unit of plasma had 
been transfused. This was insufficient in relation to the 
patients' weight, as obtained from the medical records.
Given that information on patients' height and weight 
could not be obtained from the information systems, in 
the 302 cases for which the medical records were not 
analysed, the general rule was applied that one unit 
of plasma was to be considered insufficient while the 
transfusion of two or more units was appropriate.
For two treatments judged inappropriate and for one 
treatment judged appropriate the third opinion of the 
senior reviewer was needed. 
In conclusion, the results of our study have 
demonstrated that about 97% of the plasma use in 
Fondazione was in line with internal guidelines, which, 
in turn, were drawn up on the basis of national and 
international guidelines.
Discussion
The potentiality of the "record linkage" analytical 
method was exploited to set up a systematic review of 
all the plasma transfused during the year 2012.
Using the demographic, clinical and laboratory 
information about patients, summarised in the PPP, it was 
possible to assess the laboratory tests performed on the 
days on which a patient received a FFP transfusion and in 
the following days. These were also associated with any 
information relating to surgical or invasive procedures 
performed during the same hospital admission. It 
was then possible to assess the appropriateness or 
inappropriateness of the FFP transfusions administered.
The very high level of appropriateness found, higher 
than the levels emerging from the literature36-41, can 
be explained by various factors. In the first place, the 
departments of the Fondazione that mainly request FFP 
are surgical, intensive care, emergency, resuscitation 
units and, especially, the liver transplant centre. This 
last, in particular, admits patients who often have a 
clear necessity for FFP transfusions taking into account 
their primary disease, clinical picture or surgery needed. 
Secondly, the Fondazione had set up computerised audit 
activities over the years4,5, together with continuous 
updating of internal protocols28. Both of these are valid 
guides for the departments and for correct clinical 
practice. Last but not least, the ongoing collaboration 
with colleagues at the Coagulation Centre has ensured a 
readily available advisory service. This has undoubtedly 
contributed greatly to appropriate handling of transfusion 
requests by the various departments. 
In this way, the strategic management leadership of 
the Fondazione was fully assured that the use of FFP 
was appropriate and that the increased use of plasma 
transfusions complied with the hospital's protocols 
and best practices. It is, therefore, possible to conclude 
that the smaller amount of plasma sent to industry for 
fractionation was not caused by inappropriate use of FFP 
but was justified by increased clinical needs.
The record linkage system also enabled a 
comprehensive overview of the activities of our 
Transfusion Centre and, especially, of its single 
departments, resulting in an assessment of the workload 
distribution and the transfusion requests.
Nevertheless, certain limits emerged, especially 
with regards to premature neonates, for whom careful 
examination of the paper medical records is still required 
on account of the clinical complexities, and also because 
of the difficulty of obtaining computerised information 
on blood tests that are not performed routinely in this 
population of patients. 
Other limits to this analytical system derive from the 
fact that, as of now, data referring to outpatients' treatment 
are not sufficiently computerised to enable assessment 
of these patients. As described in the literature, an 
analysis of the appropriateness of plasma transfusion is 
also expected to take into account the patient's weight, 
a variable that is not presently retrievable from the 
information systems of the Fondazione36-41.
From a data management point of view, the analysis 
revealed that the various laboratories collaborating 
with the central laboratory do not use the same patient 
identification codes. This makes it more difficult 
to retrieve all the information regarding a given 
period and to perform the record linkage for a given 
patient if there is a lack of information at the central 
laboratory. Harmonisation of patients' identification 
Table IV - Distribution of adult patients assessed in relation 
to the pathological conditions for which use of 
fresh-frozen plasma is deemed appropriate.
Pathological condition Cases
Correction of congenital or acquired deficiencies of single 
coagulation factors 3
Correction of acquired deficiencies of multiple coagulation 
factors 130
Severe liver disease 140
Acute disseminated intravascular coagulation 7
Correction of microvascular bleeding 114
Apheresis in thrombotic microangiopathies (thrombotic 
thrombocytopenic purpura, haemolytic uraemic syndrome, 
haemolysis, elevated liver enzymes and low platelet count 
- HELLP) 
9
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codes throughout the secondary information systems 
of the Fondazione is certainly an area for the future 
improvement of this analytical system.
Conclusions
The "record linkage" analytical method, which 
assembles information regarding each single patient 
from several data sources, proved to be very rapid 
since a great deal of information was retrieved from 
the hospital information systems alone. It was also 
efficient since it enabled analysis of a wider range of 
cases than other methods and, lastly, it was effective 
since the manual review of the medical records, aimed 
at retrieving the few, well-identified data not contained 
in the computerised profiles, was necessary for only 
25% of the entire population receiving transfusions. 
In spite of the limits stated in the discussion, record linkage 
remains an extremely valid and efficient system for assessing 
activities, since it enables analysis of a wide range of cases 
and, notwithstanding the lack of certain data (e.g. the patient's 
weight), allows the assessment of the appropriateness of FFP 
transfusion on a prevalently clinical basis.
The assessment described paved the way to further 
audit programs using record linkage techniques 
to produce a huge factual base for clinical and 
organisational improvements. 
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